American Heart Journal
Volume 155, Issue 6 , Pages 1075-1080 , June 2008

Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents

  • Mehdi H. Shishehbor, DO, MPH

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Reza Amini, MD

      Affiliations

    • Internal Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Russell E. Raymond, DO

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Anthony A. Bavry, MD, MPH

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Sorin J. Brener, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Samir R. Kapadia, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Patrick L. Whitlow, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Stephen G. Ellis, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Deepak L. Bhatt, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • Corresponding Author InformationReprint requests: Deepak L. Bhatt, MD, FACC, FSCAI, FESC, Department of Cardiovascular Medicine, Desk F-25, 9500 Euclid Ave, Cleveland, OH 44195.

Received 1 October 2007 ,Accepted 22 January 2008.

References 

  1. Schampaert E, Cohen EA, Schluter M, et al. The Canadian Study of the Sirolimus-eluting Stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110–1115
  2. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
  3. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947
  4. Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries. Initial results of a multicenter experience. Circulation. 1992;86:1836–1844
  5. Kastrati A, Elezi S, Dirschinger J, et al. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol. 1999;83:1617–1622
  6. Kereiakes DJ, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol. 2006;48:21–31
  7. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215–1223
  8. Petronio AS, De Carlo M, Branchitta G, et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. J Am Coll Cardiol. 2007;49:539–546
  9. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112:270–278
  10. Chu WW, Kuchulakanti PK, Torguson R, et al. Comparison of clinical outcomes of overlapping sirolimus- versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2006;98:1563–1566
  11. Lee CW, Park KH, Kim YH, et al. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol. 2006;98:918–922
  12. Tsagalou E, Chieffo A, Iakovou I, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol. 2005;45:1570–1573
  13. Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation. 2005;112:906–915discussion 923
  14. Curfman GD, Morrissey S, Jarcho JA, et al. Drug-eluting coronary stents—promise and uncertainty. N Engl J Med. 2007;356:1059–1060
  15. Farb A, Boam AB. Stent thrombosis redux—the FDA perspective. N Engl J Med. 2007;356:984–987
  16. Maisel WH. Unanswered questions—drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356:981–984
  17. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306–3313
  18. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  19. Moses JW, Stone GW, Nikolsky E, et al. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. J Am Coll Cardiol. 2006;47:2164–2171
  20. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  21. Sousa JE, Costa MA, Abizaid A, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation. 2005;111:2326–2329
  22. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007–2011
  23. Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation. 2004;109:196–200
  24. Weissman NJ, Koglin J, Cox DA, et al. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1201–1205
  25. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005;294:819–825

☆ This is supported in part by the National Institutes of Health, National Institute of Child Health and Human Development, Multidisciplinary Clinical Research Career Development Programs grant K12 HD049091 and the National Institutes of Health Loan Repayment Program (Dr Shishehbor).

☆☆ MHS, RA, AAB, SJB, SRK have no conflict of interest to report. RER serves on the Boston Scientific speaker's bureau. DLB discloses the following relationships: research grants (directly to the institution)—Bristol Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi Aventis, and The Medicines Company; honoraria (donated to nonprofits for >2 years)—Astra Zeneca, Bristol Myers Squibb, Centocor, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Sanofi Aventis, Schering Plough, The Medicines Company, and tns Healthcare; speaker's bureau (>2 years ago)—Bristol Myers Squibb, Sanofi Aventis, and The Medicines Company; consultant/advisory board (donated to nonprofits for >2 years)—Astellas, Astra Zeneca, Bristol Myers Squibb, Cardax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson&Johnson, McNeil, Medtronic, Millennium, Molecular Insights, Otsuka, Paringenix, PDL, Philips, Portola, Sanofi Aventis, Schering Plough, Scios, Takeda, The Medicines Company, tns Healthcare, and Vertex; expert testimony regarding clopidogrel (>2 years ago; the compensation was donated to a nonprofit organization); Cleveland Clinic Coordinating Center currently receives or has received research funding from Abraxis, Alexion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardionet, Centocor, Converge Medical Inc, Cordis, Dr Reddy's, Edwards Lifesciences, Esperion, GE Medical, Genentech, Gilford, GSK, Guidant, J&J, Kensey-Nash, Lilly, Medtronic, Merck, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering Plough, Scios, St Jude Medical, Takeda, TMC, VasoGenix, and Viacor. SGE serves on the advisory board of Cordis and Boston Scientific Inc. PLW serves as a consultant and/or on the advisory board of ICON Interventional Systems and Medlogics.

PII: S0002-8703(08)00063-X

doi: 10.1016/j.ahj.2008.01.017

American Heart Journal
Volume 155, Issue 6 , Pages 1075-1080 , June 2008

Article Tools